F2 and Sepsis: The currently approved therapeutic dose of 24 μg/kg/hr (for 96 hours) of DAA for the treatment of severe sepsis patients partially (reduced by about 25%) blunted thrombin formation, as evidenced by reduction of D-dimer levels, prothrombin fragment F1.2, and thrombin-antithrombin complex [12,16].